Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: A meta-analysis of randomized controlled trials

European Journal of Clinical Pharmacology

Volumn 66, Issue 11, 2010, Pages 1099-1108

  Cao, Yong Bing ^a   Zhang, Jun Dong ^a   Shen, Hui ^b   Jiang, Yuan Ying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Anticoagulants; Embolism; Meta analysis; Prophylaxis; Thrombosis

Indexed keywords

ENOXAPARIN; RIVAROXABAN;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; HUMAN; META ANALYSIS; MORNING DOSAGE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; DOUBLE-BLIND METHOD; ENOXAPARIN; HEMORRHAGE; HUMANS; INCIDENCE; MORPHOLINES; MULTICENTER STUDIES AS TOPIC; ODDS RATIO; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 78649319886     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0889-z     Document Type: Article

References (26)

1. WH Geerts D Bergqvist GF Pineo JA Heit CM Samama MR Lassen CW Colwell 2008 Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn Chest 133 381S 453S 1:CAS:528:DC%2BD1cXptVKhsrg%3D 10.1378/chest.08-0656 18574271 (Pubitemid 351894916)
2. DN Mohr MD Silverstein PA Murtaugh JM Harrison 1993 Prophylactic agents for venous thrombosis in elective hip surgery: meta-analysis of studies using venographic assessment Arch Intern Med 153 2221 2228 1:STN:280: DyaK2c%2FivFeitA%3D%3D 10.1001/archinte.153.19.2221 8215725 (Pubitemid 23296488)
3. RJ Friedman 2003 Extended thromboprophylaxis after hip or knee replacement Orthopedics 26 2 Suppl s225 s230 12597230
4. WH Geerts JA Heit GP Clagett GF Pineo CW Colwell FA Anderson Jr HB Wheeler 2001 Prevention of venous thromboembolism Chest 119 132S 175S 1:CAS:528:DC%2BD3MXhtlamsrY%3D 10.1378/chest.119.1-suppl.132S 11157647
5. J Ansell J Hirsh L Poller H Bussey A Jacobson E Hylek 2004 The pharmacology and management of the vitamin K antagonists. In: 7th ACCP Conf Antithrombotic and Thrombolytic Therapy Chest 126 Suppl 204S 233S 1:CAS:528:DC%2BD2cXptV2msLw%3D 10.1378/chest.126.3-suppl.204S 15383473 (Pubitemid 39297955)
6. LM Davies GA Richardson AT Cohen 2000 Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery Value Health 3 397 406 1:STN:280:DC%2BD28%2FnvFCmtQ%3D%3D 10.1046/j.1524-4733.2000.36005.x 16464199 (Pubitemid 32066647)
7. OE Dahl AM Pleil 2003 Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement J Thromb Haemost 1 896 906 1:CAS:528:DC%2BD3sXmvFSgtLw%3D 10.1046/j.1538-7836.2003.00236.x 12871354
8. RJ Friedman AS Gallus FD Cushner G Fitzgerald FA Anderson Jr 2008 Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty Curr Med Res Opin 24 87 97 18028586
9. E Perzborn J Strassburger A Wilmen J Pohlmann S Roehrig KH Schlemmer A Straub 2005 In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor J Thromb Haemost 3 514 521 1:CAS:528:DC%2BD2MXjtVymsb4%3D 10.1111/j.1538-7836.2005.01166.x 15748242 (Pubitemid 41632877)
10. AG Turpie MR Lassen BL Davidson KA Bauer M Gent LM Kwong FD Cushner PA Lotke SD Berkowitz TJ Bandel A Benson F Misselwitz WD Fisher 2009 Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 1673 1680 1:CAS:528: DC%2BD1MXmtVWjtL4%3D 10.1016/S0140-6736(09)60734-0 19411100
11. BI Eriksson LC Borris RJ Friedman S Haas MV Huisman AK Kakkar TJ Bandel H Beckmann E Muehlhofer F Misselwitz W Geerts 2008 Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2765 2775 1:CAS:528:DC%2BD1cXnvFahtbo%3D 10.1056/NEJMoa0800374 18579811 (Pubitemid 351930851)
12. MR Lassen W Ageno LC Borris JR Lieberman N Rosencher TJ Bandel F Misselwitz AG Turpie 2008 Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2776 2786 1:CAS:528: DC%2BD1cXnvFagt70%3D 10.1056/NEJMoa076016 18579812 (Pubitemid 351930852)
13. AK Kakkar B Brenner OE Dahl BI Eriksson P Mouret J Muntz AG Soglian AF Pap F Misselwitz S Haas 2008 Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 31 39 1:CAS:528:DC%2BD1cXotlWqsrg%3D 10.1016/S0140-6736(08)60880-6 18582928
14. BI Eriksson LC Borris OE Dahl S Haas MV Huisman AK Kakkar F Misselwitz E Muehlhofer P Kälebo 2007 Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb Res 120 685 693 1:CAS:528:DC%2BD2sXpsFKrtrg%3D 10.1016/j.thromres.2006.12.025 17292948 (Pubitemid 47268049)
15. BI Eriksson LC Borris OE Dahl S Haas MV Huisman AK Kakkar E Muehlhofer C Dierig F Misselwitz P Kälebo 2006 A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement Circulation 114 2374 2381 1:CAS:528:DC%2BD28Xht1Wqu77L 10.1161/CIRCULATIONAHA.106.642074 17116766 (Pubitemid 44847454)
16. BI Eriksson L Borris OE Dahl S Haas MV Huisman AK Kakkar F Misselwitz P Kälebo 2006 Direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement J Thromb Haemost 4 121 128 1:CAS:528:DC%2BD28Xpt1WgsQ%3D%3D 10.1111/j.1538-7836.2005.01657.x 16409461
17. AG Turpie WD Fisher KA Bauer LM Kwong MW Irwin P Kälebo F Misselwitz M Gent 2005 BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study J Thromb Haemost 3 2479 2486 1:CAS:528:DC%2BD2MXht1KktLzP 10.1111/j.1538-7836.2005.01602.x 16241946 (Pubitemid 41727165)
18. AR Jadad RA Moore D Carroll C Jenkinson DJ Reynolds DJ Gavaghan HJ McQuay 1996 Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1 12 1:STN:280:DyaK28zgvVCmug%3D%3D 10.1016/0197-2456(95)00134-4 8721797 (Pubitemid 26120810)
19. KS Khan S Daya A Jadad 1996 The importance of quality of primary studies in producing unbiased systematic reviews Arch Intern Med 156 661 666 1:STN:280:DyaK283gsF2qsA%3D%3D 10.1001/archinte.156.6.661 8629879 (Pubitemid 26095017)
20. D Moher AR Jadad P Tugwell 1996 Assessing the quality of randomized controlled trials. Current issues and future directions Int J Technol Assess Health Care 12 195 208 1:STN:280:DyaK283pt12quw%3D%3D 10.1017/S0266462300009570 8707495
21. National Collaborating Centre for Acute Care (2007) Venous thromboembolism. Reducing the risk of venous Thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. National Collaborating Centre for Acute Care, The Royal College of Surgeons of England, London. Available at: http://www.rcseng.ac.uk/surgical-research-units/nccac/ guidelines/venous-thrombo-guideline.html
22. BI Eriksson AK Kakkar AG Turpie M Gent TJ Bandel M Homering F Misselwitz MR Lassen 2009 Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement J Bone Joint Surg Br 91 636 644 1:STN:280:DC%2BD1MzhtlGmug%3D%3D 10.1302/0301-620X.91B5.21691 19407299
23. K Rabinov S Paulin 1972 Roentgen diagnosis of venous thrombosis in the leg Arch Surg 104 134 144 1:STN:280:DyaE38%2Fpt1Klsw%3D%3D 5008903
24. P Kälebo S Ekman S Lindbratt BI Eriksson U Pauli BE Zachrisson P Close 1996 Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment Thromb Haemost 76 893 896 8972007
25. J Lau JPA Ioannidis CH Schmid 1997 summing up the evidence: one answer is not always enough Lancet 351 123 127 10.1016/S0140-6736(97)08468-7
26. SG Thompson 1994 Why sources of heterogeneity in meta-analysis should be investigated Br Med J 309 1351 1355 1:STN:280:DyaK2M7ntVelsQ%3D%3D